Remove Clinical Trials Remove FDA Approval Remove Pharmacy
article thumbnail

Journey Medical’s Emrosi Wins FDA Approval for Rosacea, Could Rival Galderma’s Oracea

XTalks

Emrosi’s approval was based on data from a pair of Phase III clinical trials for the treatment of rosacea. The trials met all co-primary and secondary endpoints, with participants having successfully completed the 16-week treatment with no significant safety issues.

article thumbnail

The FDA Just Approved The First Fast-Acting Nasal Spray For Migraines

AuroBlog - Aurous Healthcare Clinical Trials blog

The US Food and Drug Administration has approved a fast-acting nasal spray from Pfizer designed to treat migraines, the US pharmaceutical giant said Friday.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA grants approval for Amylyx’s Relyvrio to treat ALS

Pharmaceutical Technology

The FDA approval is based on findings from the multicentre Phase II CENTAUR clinical trial that enrolled 137 ALS patients. For the first three weeks, the recommended dose is one packet a day. Following this time period, the dosage is raised to one packet twice daily.

article thumbnail

Ogsiveo Receives FDA Approval as First Therapy for Desmoid Tumors

XTalks

Pfizer spinout SpringWorks Therapeutics’ Ogsiveo (nirogacestat) has received US Food and Drug Administration (FDA) approval for the treatment of desmoid tumors, an ultra-rare subtype of non-cancerous soft tissue sarcomas that can cause severe pain and disfigurement.

article thumbnail

FDA Approves First Eylea Interchangeable Biosimilars Yesafili and Opuviz

XTalks

Yesafili and Opuviz are approved to treat the same conditions as Regeneron’s vascular endothelial growth factor (VEGF) inhibitor Eylea — neovascular (wet) age-related macular degeneration (AMD), diabetic retinopathy, macular edema following retinal vein occlusion (RVO) and diabetic macular edema (DME). According to Biocon, there are 19.8

article thumbnail

NeuroMetrix’s Quell Device Gets FDA Approval as First Non-Drug Treatment for Fibromyalgia

XTalks

On Thursday, the FDA granted De Novo authorization for NeuroMetrix to market the Quell® wearable neuromodulation device for treating fibromyalgia. This approval is significant because prior to Quell, there were no FDA-approved medical devices for fibromyalgia treatment.

article thumbnail

New Zepbound TV Commercial Inspires ‘Change’

XTalks

This translates to an average weight loss of 21%, which was demonstrated in clinical trials (over a period of 72 weeks) that supported Zepbounds FDA approval. This month, Zepbound won FDA approval for obstructive sleep apnea (OSA) , making it the first approved drug for the condition.